Aileen Healy

Dr. Healy has over 15 years of experience in disease biology, leading independent research efforts in the areas of neuroscience, cardiovascular pathophysiology, oncology and inflammation. From 2001 until 2008, Dr. Healy held positions of increasing responsibility at Momenta Pharmaceuticals and Millennium Pharmaceuticals. Her prior preclinical research in drug discovery and development included significant contributions to target identification, lead optimization, in vivo pharmacology and biomarker discovery for small molecules and biologics. Before taking those positions, Dr. Healy was a faculty member at Boston University School of Medicine, where her research focused on cellular and molecular mechanisms of pulmonary development and disease. Dr. Healy holds patents and has published in peer-reviewed journals on a wide range of topics including biomarkers and the molecular mechanisms of disease. Dr. Healy received her PhD in cellular biology at Tufts University Medical School and completed her postdoctoral training in the molecular biology of the blood vessel wall at the Massachusetts Institute of Technology.